Blood purification in intensive care patients with multiple organ dysfunction syndrome and sepsis after cardiac surgery

Abstract

Extracorporeal blood purification is becoming increasingly important in intensive therapy for multiple organ dysfunction syndrome (MODS) and sepsis, considering all of their pathophysiological aspects. The results of treatment, particularly in children, considering their anatomical and physiological features, are related to the severity and progression of organ failure, the indications that are found, the choice of method, and the timely initiation of blood purification. Multiple organ support therapy is the aim of introducing and applying blood purification today. Various extracorporeal blood purification techniques directly affect the molecular and electrolyte composition of blood and influence all structures of the human body, which can allow us to correct, recover, replace and maintain homeostasis in MODS. The potential of new extracorporeal molecular technologies allows their successful use in severe cardiac and respiratory failure, acute kidney injury and hepatic dysfunction and in complex therapy for severe infections and sepsis and extreme metabolic violations. Adult and pediatric patients after cardiac surgery with cardiopulmonary bypass form a special cohort that often requires the application of various intra- and extracorporeal techniques due to the development of MODS, infections and sepsis in the postoperative period.

Keywords

Extracorporeal blood purification / acute kidney injury / acute liver failure / extracorporeal membrane oxygenation / sepsis / selective lipopolysaccharide-adsorption / critical condition / cardiovascular surgery

References

[1] Uchino S,Bellomo R,Morimatsu H,Schetz M,Bouman C,Gibney N,Ronco C.Acute renal failure in critically ill patients: a multinational, multicenter study..JAMA2005;294:813-8

[2] Bellomo R.Continuous renal replacement therapy: hemofiltration, hemodiafiltration or hemodialysis..In: Ronco C, Bellomo R, Kellum JA, editors. Critical Care Nephrology. 2nd ed.2009;PhiladelphiaSaunders Elsevier1354-8

[3] Hoste EA.Incidence, classification, and outcomes of acute kidney injury..Contrib Nephrol2007;156:32-8

[4] Blinder JJ,Lee VV,Fraser CD,Jefferies JL.Congenital heart surgery in infants: effects of acute kidney injury on outcomes..J Thorac Cardiovasc Surg2012;143:368-74

[5] Kaddourah A.Renal replacement therapy in neonates..Clin Perinatol2014;41:517-27

[6] Gulla KM,Gupta D,Anand K.Continuous renal replacement therapy in children with severe sepsis and multiorgan dysfunction - a pilot study on timing of initiation..Indian J Crit Care Med2015;19:613-7 PMCID:PMC4637963

[7] Palevsky PM.Renal replacement therapy in acute kidney injury..Adv Chronic Kidney Dis2013;20:76-84 PMCID:PMC3531877

[8] Ronco C,De Backer D,Taccone FS,Pickkers P,Turani F,Bellomo R,Antonelli M,Prowle JR.Renal replacement therapy in acute kidney injury: controversy and consensus..Crit Care2015;19:146 PMCID:PMC4386097

[9] Bridges BC,Smith J.Pediatric renal replacement therapy in the intensive care unit..Blood Purif2012;34:138-48 PMCID:PMC5545793

[10] Goldstein SL.Advances in pediatric renal replacement therapy for acute kidney injury..Semin Dial2011;24:187-91

[11] Bojan M,Vouhé PR,Pouard P.Early initiation of peritoneal dialysis in neonates and infants with acute kidney injury following cardiac surgery is associated with a significant decrease in mortality..Kidney Int2012;82:474-81

[12] Ponce D,Amerling R.Advances in peritoneal dialysis in acute kidney injury..Blood Purif2012;34:107-16

[13] Jander A,Pagowska-Klimek I,Moll J,Nowicki M.Continuous veno-venous hemodiafiltration in children after cardiac surgery..Eur J Cardiothorac Surg2007;31:1022-8

[14] Iarustovskiĭ MB,Strakhov DG,Geptner RA,Shipova EA.A present-day variant of intermittent replacement renal therapy in patients with multiple organ failure after cardiovascular surgery..Anesteziol Reanimatol2002;(2):49-54

[15] Askenazi DJ,Paden ML,Bridges BC,Fleming GM.Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation..Clin J Am Soc Nephrol2012;7:1328-36 PMCID:PMC5486859

[16] Hoover NG,Reid C,Rogers K,Paden ML.Enhanced fluid management with continuous venovenous hemofiltration in pediatric respiratory failure patients receiving extracorporeal membrane oxygenation support..Int Care Med2008;34:2241-7

[17] Shaheen IS,Watson AR,Mayer A.Continuous venovenous hemofiltration with or without extracorporeal membrane oxygenation in children..Pediatr Crit Care Med2007;8:362-5

[18] Chen H,Yin N.Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in critically ill patients: a systematic review..Crit Care2014;18:675 PMCID:PMC4277651

[19] Fleming GM,Bridges BC,Paden ML,Zappitelli M.A multicenter international survey of renal supportive therapy during ECMO: the Kidney Intervention During Extracorporeal Membrane Oxygenation (KIDMO) group..ASAIO J2012;58:407-14 PMCID:PMC5486948

[20] Yaroustovsky MB,Nazarova EI.Continuous hemofiltration in a single circuit with extracorporeal membrane oxygenation in children with critical heart failure after cardiac surgery..Clin Experiment Surg Petrovsky J2017;5:59-67

[21] Gupta P,Chipman CW,Gossett JM,Bhutta AT.20-year experience of prolonged extracorporeal membrane oxygenation in critically ill children with cardiac or pulmonary failure..Ann Thorac Surg2012;93:1584-90

[22] Daas M,Wijdicks EF,Wiesner RH,Dunn WF.Acute liver failure: results of 5 years clinical protocol..Liver Transpl Surg1995;1:210-9

[23] Cochran JB.Acute liver failure in children..Pediatr Emerg Care2007;23:129-35

[24] Lee WS,Kelly DA.Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom..J Pediatr Gastroenterol Nutr2005;40:575-81

[25] Saliba F,Durand F,Letierce A,Barange K,Belnard M,Samuel D.Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial..Ann Intern Med2013;159:522-31

[26] Stange J,Mehta R,Bartlett RH.The molecular adsorbent recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial and clinical experience from 19 centers..Artif Organs2002;26:103-40

[27] Larsen FS,Bernsmeier C,Isoniemi H,Triantafyllou E,Auzinger G,Eefsen M,Clemmesen JO,Frederiksen HJ,Antoniades CG.High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial..J Hepatol2016;64:69-78

[28] Davenport A.Extracorporeal support for patients with hepatic failure..Hemodial Int2003;7:256-63

[29] Saliba F.Artificial liver support: a real step forward..Minerva Med2015;106:35-43

[30] Ba-ares R,Larsen FS,Albillos A,Saliba F,Klammt S,Pares A,Brünnler T,Mathurin P,Gasbarrini A,Wilmer A,Eefsen M,Zipprich A,Pavesi M,Mitzner S,Arroyo V.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial..Hepatology2013;57:1153-62

[31] Kribben A,Haag S,Treichel U,Sarrazin C,Van Vlierberghe H,Hafer C,Galle PR,Caraceni P,Salmhofer H,Ginès P,Rifai K.Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure..Gastroenterology2012;142:782-9

[32] Rosenthal P.Is the molecular adsorbent recirculating system the answer for children with acute liver failure?.Liver Transpl2015;21:277-8

[33] Schaefer B.The role of molecular adsorbent recirculating system dialysis for extracorporeal liver support in children..Pediatr Nephrol2013;28:1763-9

[34] Yaroustovsky MB,Komardina EV.Methods of molecular transfusion in intensive care of critical states in pediatric postoperative cardiac surgery patients..Ann Russ Acad Med Sci2016;71:341-9

[35] Mitzner SR,Klammt S,Erley CM,Berger ED,Peszynski P,Hickstein H,Löhr JM,Emmrich J,Schmidt R.Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial..Liver Transpl2000;6:277-86

[36] Vaid A,Balk EM.Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis..ASAIO J2012;58:51-9

[37] Laleman W,Evenepoel P,Zeegers M,Verslype C,Nevens F.Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study..World J Gastroenterol2008;14:2065-71 PMCID:PMC2701529

[38] Oppert M,Petrasch K.Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit..Ther Apher Dial2009;13:426-30

[39] Yaroustovsky MB,Komardina EV,Nazarova EI,Geptner RA.Extracorporeal methods of hematological correction in patients with acute liver insufficiency after cardiac surgery..Anesteziol Reanimatol2014;59:4-10

[40] Meijers BKI,Nevens F,Bammens B,Arnout J,Evenepoel P.Major coagulation disturbances during fractionated plasma separation and adsorption..Am J Transplant2007;7:2195-9

[41] Gong D,Zhu D,Liu Z.Efficient removal of serum bilirubin by a novel artificial liver support system using albumin convection: a pilot study..Blood Purif2012;34:201-8

[42] Donati G,Cianciolo G,Carretta E,Panicali L,Piscaglia F,Colì L.Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up..Artif Organs2014;38:125-34

[43] Tsipotis E,Jaber BL.Albumin dialysis for liver failure: a systematic review..Adv Chronic Kidney Dis2015;22:382-90

[44] Yaroustovsky MB,Krotenko NP.Methods of molecular transfusion in the intensive therapy of critical states..Ann RussAcad Med Sci2016;71:281-7

[45] Rifai K,Gerken G,Herget-Rosenthal S,Betz C,Van Vlierberghe H,Escorsell A,Hafer C,Galle PR,Caraceni P,Berr F,Kozik-Jaromin J.Extracorporeal liver support by fractionated plasma separation and adsorption (Prometheus) in patients with acute-on-chronic liver failure (HELIOS study): a prospective randomized controlled multicenter study..J Hepatol2010;52:S3

[46] Marshall JC.Endotoxin in the pathogenesis of sepsis..Contrib Nephrol2010;167:1-13

[47] Hanna W.Pediatric sepsis: challenges and adjunctive therapies..Crit Care Clin2013;29:203-22 PMCID:PMC3612267

[48] Kaukonen KM,Suzuki S,Bellomo R.Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012..JAMA2014;311:1308-16

[49] Berthet J,Hamzeh-Cognasse H,Eyraud MA,Pozzetto B,Garraud O.Human platelets can discriminate between various bacterial LPS isoforms via TLR4 signaling and differential cytokine secretion..Clin Immun2012;145:189-200

[50] Bosmann M.The inflammatory response in sepsis..Trends Immunol2013;34:129-36 PMCID:PMC3543471

[51] Dellinger RP,Rhodes A,Gerlach H,Sevransky JE,Douglas IS,Osborn TM,Townsend SR,Kleinpell RM,Deutschman CS,Rubenfeld GD,Beale RJ,Moreno R.Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012..Crit Care Med2013;41:580-637

[52] Zhou F,Murugan R.Blood purification and mortality in sepsis: a meta-analysis of randomized trials..Crit Care Med2013;41:2209-20 PMCID:PMC3758418

[53] Yaroustovsky M,Krotenko N,Plyushch M.A pilot study of selective lipopolysaccharide adsorption and coupled plasma filtration and adsorption in adult patients with severe sepsis..Blood Purif2015;39:210-7

[54] Yaroustovsky M,Krotenko N,Plyushch M,Nazarova H.Combined extracorporeal therapy for severe sepsis in patients after cardiac surgery..Blood Purif2014;37:39-46

[55] Kojika M,Yaegashi Y,Suzuki K.Endo S: Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity..Ther Apher Dial2006;10:12-8

[56] Cruz DN,Fumagalli R,Brienza N,Malcangi V,Volta G,Rottoli F,Ronco C.Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial..JAMA2009;301:2445-52

[57] Marshall JC,Vincent JL,Cohen J,Opal S,Brett SJ,Mehta S,Romaschin A.Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study..J Infect Dis2004;190:527-34

[58] Cruz DN.Polymyxin B hemoperfusion: matching the cure to the disease..Crit Care Med2014;42:1309-10

[59] Mitaka C,Kawada K,Imai T.A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock..Shock2009;32:478-83

[60] Tanaka Y,Tsuchiya K,Nitta K.Polymyxin B hemoperfusion improves hemodynamic status in patients with sepsis with both Gram-negative and non-Gram-negative bacteria..J Clin Exp Nephrol2016;1:4

[61] Takahashi M,Kawakubo H,Takahashi T,Saikawa Y,Kitagawa Y.Effectiveness of polymyxin B-direct hemoperfusion (PMX-DHP) therapy using a polymyxin B-immobilized fiber column in patients with post-esophagectomy sepsis..Esophagus2014;11:189-96

[62] Vincent JL,Cohen J,Bruining H,Wittebole X,Brett S,Nakamura H.A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection..Shock2005;23:400-5

[63] Cruz DN,Bellomo R,Polanco N,Lentini P,Ueno T,Ronco C.Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review..Crit Care2007;11:R47 PMCID:PMC2206475

[64] Berto P,Cruz D,Antonelli M.Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy..Blood Purif2011;32:331-40

[65] Berlot G,Tomasini A,Gerini U,Giudici F.Effects of the volume of processed plasma on the outcome, arterial pressure and blood procalcitonin levels in patients with severe sepsis and septic shock treated with coupled plasma filtration and adsorption..Blood Purif2014;37:146-51

[66] Haase M,Baldwin I,Fealy N,Morgera S,Storr M,Neumayer HH.Hemodialysis membrane with a high-molecular-weight cut-off and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial..Am J Kidney Dis2007;50:296-304

[67] Rimmelé Th.Clinical review: blood purification for sepsis..Crit Care2011;15:205 PMCID:PMC3222040

[68] Esteban E,Alsina L.Immunomodulation in sepsis: the role of endotoxin removal by polymyxin B-immobilized cartridge..Mediators Inflamm2013;2013:507539

[69] Yaroustovsky M,Krotenko N,Plyushch M.Endotoxin adsorption using polymyxin B immobilised fibre cartridges in severe sepsis patients following cardiac surgery..Int J Artif Organs2014;37:299-307

[70] Hu D,Zhu B,Wang L,Zhao W.Effects of coupled plasma filtration adsorption on septic patients with multiple organ dysfunction syndrome..Ren Fail2012;34:834-9

[71] Lee D,Haase-Fielitz A,Goehl H.A pilot, randomized, double-blind, cross-over study of high cut-off versus high-flux dialysis membranes..Blood Purif2009;28:365-72

[72] Morgera S,Kuss T,Zuckermann-Becker H,Krieg H,Bellomo R.Pilot study of the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure..Crit Care Med2006;34:2099-104

[73] Naka T,Bellomo R."Super high-flux" or "high cut-off" hemofiltration and hemodialysis..Contrib Nephrol2010;166:181-9

[74] Liu JP,Qie LP.Disease indicators for sepsis and analysis of sepsis treatment in children using the continuous blood purification technique..Genet Mol Res2015;4:5685-93

[75] Hirakawa E,Tokuhisa T,Hayashida Y,Matsui T,Inoue T.Septic neonate rescued by polymyxin B hemoperfusion..Pediatr Int2013;55:e70-2

[76] Morishita Y,Ohtake K,Hishikawa S,Kawarasaki H.Successful treatment of sepsis with polymyxin-B immobilized fiber hemoperfusion in a child after living donor liver transplantation..Dig Dis Sci2005;50:757